According to Ministry of Health and population statistics in 2017
triSure is a non-invasive prenatal screening test that uses cell-free foetal DNA released into maternal blood for early detection of foetal risk of serious birth defects, which are common due to numerical chromosome abnormalities.
triSure employs Next-Generation Sequencing technology, Illumina, USA and is the only NIPT test in Vietnam developed based on a genetic database of more than 200,000 pregnant Vietnamese women, with an outstanding accuracy of >99%.
Early detection of common genetic birth defects in the foetus helps early intervention and creates an opportunity for parents to manage pregnancy plans more effectively, while preparing for the next pregnancy.
– The triSure algorithm is the world’s first additive algorithm to help differentiate between foetal and maternal DNA, recognize maternal mosaicism and foetal abnormalities, and increase test accuracy.
– triSure is the NIPT test that reduces the need for amniocentesis, 25 times more than other screening tests**.
– triSure helps to minimise false positive cases (positive test results when the foetus is really disease-free)***
(*) International publication “Establishing and validating non-invasive prenatal testing procedure for foetal aneuploidies in Vietnam”.
(**) Published in the Vietnamese Medical Journal “Investigate positive predictive values of NIPT triSure noninvasive prenatal test in medical practice” by Patricia AT, et al (2016); “Noninvasive prenatal testing in the general obstetric population: clinical performance and counselling considerations in over 85,000 cases”, Prenatal Diagnosis, 36, 237 243 & Petersen AK, et al. (2017). “PPV estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory”, Am J Obstet Gynecol; 217:691. e1–6.
(***) International publication “Reducing false positive rate of foetal monosomy X in non invasive prenatal testing using a combined algorithm to detect maternal mosaic monosomy X”
Early screening for serious and common birth defects in the foetus. Early detection of common genetic birth defects in the foetus.
Performed at nine weeks or more of pregnancy and is recommended as the first test for pregnant women.
The accuracy >99% can replace biochemical tests such as double test, triple test.
Early screening for timely intervention or a better pregnancy management plan, appropriate delivery management, postnatal care and preparation for the next pregnancy.
Taking the mother’s blood and separate extracellular DNA
Sequencing of cell-free DNA
Returning results and post-test counselling
GET MEDICAL CONSULTATION FROM DOCTORS
Tư vấn di truyền